Alzamend Neuro (ALZN) FDA Approvals $0.78 -0.24 (-23.94%) Closing price 04:00 PM EasternExtended Trading$0.77 0.00 (-0.23%) As of 05:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share FDA Events Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsInsider TradesNews and TrendsOwnershipSEC Filings Alzamend Neuro's Drug in the FDA Approval ProcessThis section highlights FDA-related milestones and regulatory updates for drugs developed by Alzamend Neuro (ALZN). Over the past two years, Alzamend Neuro has reported clinical trial outcomes, regulatory submissions, approvals, and other FDA events for drugs and therapies such as AL001. For definitions of regulatory abbreviations such as NDA, BLA, or PDUFA, see the event status legend. AL001 FDA Regulatory Timeline and Events AL001 is a drug developed by Alzamend Neuro for the following indication: A Next-Generation Lithium Therapeutic Drug Candidate, in Bipolar Disorder Patients. This drug is under review by the U.S. Food and Drug Administration (FDA). Below is a timeline of key regulatory milestones for this therapy. Abstract - August 20,2026Abstract Drug: AL001Announced Date: August 20, 2026Indication: A Next-Generation Lithium Therapeutic Drug Candidate, in Bipolar Disorder PatientsOther Companies Involved: NASDAQ:ALEC AnnouncementAlzamend Neuro, Inc. announced that an abstract reporting resting-state functional magnetic resonance imaging ("fMRI") findings for AL001, Alzamend's novel organic lithium salt, has been accepted for poster presentation at Neuroscience 2026, the annual meeting of the Society for Neuroscience ("SfN"), to be held November 14–18, 2026 in Washington, DC.AI SummaryAlzamend Neuro announced that an abstract on AL001, its experimental organic lithium formulation, has been accepted for a poster presentation at Neuroscience 2026, the Society for Neuroscience’s annual meeting in Washington, D.C. The poster, scheduled for November 18, will report findings from a completed Phase 1/2A trial using advanced 7-tesla resting-state functional MRI to examine changes in brain network connectivity after treatment. The randomized crossover study involved healthy volunteers who received AL001 and standard lithium carbonate in separate treatment periods. Researchers also collected blood samples and used MRI and spectroscopy to measure lithium levels and other brain effects. The company says the trial found that AL001 matched standard lithium’s blood levels and may offer a dose-sparing benefit, with the goal of delivering lithium to the brain while reducing exposure elsewhere in the body. These results are being presented as evidence about how AL001 affects the brain; they do not establish its safety or effectiveness for patients. AL001 is being developed for bipolar disorder and other conditions.Read AnnouncementAbstract - August 18,2026Abstract Drug: AL001Announced Date: August 18, 2026Indication: A Next-Generation Lithium Therapeutic Drug Candidate, in Bipolar Disorder PatientsOther Companies Involved: NASDAQ:ALEC AnnouncementAlzamend Neuro, Inc. announced that an abstract reporting pharmacokinetic imaging data for AL001, Alzamend's novel organic lithium salt, has been accepted for oral presentation at the International Society for Magnetic Resonance in Medicine ("ISMRM") Workshop on Beyond Protons: Challenges and Advances in X-Nuclei MR, to be held from September 28 – October 1, 2026 at the Universitat Oberta de Catalunya (UOC) in Barcelona, Spain.Read AnnouncementFindings Update - April 7,2026Findings Update Drug: AL001Announced Date: April 7, 2026Indication: A Next-Generation Lithium Therapeutic Drug Candidate, in Bipolar Disorder PatientsOther Companies Involved: NASDAQ:ALEC AnnouncementAlzamend Neuro, Inc announced encouraging pharmacodynamic findings from a brain magnetic resonance spectroscopy ("MRS") analysis conducted in healthy human subjects (N=6) in a trial conducted at Massachusetts General Hospital.AI SummaryAlzamend Neuro announced encouraging pharmacodynamic findings from a brain magnetic resonance spectroscopy (MRS) analysis in six healthy human subjects in a trial conducted at Massachusetts General Hospital. The small, early study reported measurable brain changes after dosing, suggesting the investigational treatment produces detectable central nervous system effects. Based on these preliminary results, Alzamend generated pharmacodynamic hypotheses to test in future confirmatory studies. Planned patient groups include people with Alzheimer’s disease, bipolar disorder (BD), major depressive disorder (MDD), and post‑traumatic stress disorder (PTSD). The company highlighted AL001 as a differentiated lithium therapy aimed at addressing a large unmet need in these conditions. These findings are exploratory and come from a very small sample (N=6). Alzamend plans larger, confirmatory trials using MRS and other measures to validate the signals and guide further clinical development of AL001.Read AnnouncementTop-line data - March 26,2026Top-Line Data Drug: AL001Announced Date: March 26, 2026Indication: A Next-Generation Lithium Therapeutic Drug Candidate, in Bipolar Disorder PatientsOther Companies Involved: NASDAQ:ALEC AnnouncementAlzamend Neuro, Inc. announced positive topline data from its first Phase II "Lithium in Brain" clinical trial in healthy human subjects, demonstrating that AL001 meets bioequivalence standards while also showing numerically superior lithium delivery to the brain compared to standard lithium carbonate across all 26 measured brain regions including whole brain.AI SummaryAlzamend Neuro announced positive topline results from its first Phase II "Lithium in Brain" trial in healthy volunteers. The company reported that AL001 met bioequivalence standards while also delivering numerically higher lithium levels to the brain than standard lithium carbonate. This advantage was seen across all 26 brain regions measured, including the whole brain, suggesting AL001 can match systemic exposure yet provide greater brain delivery. The study used a randomized crossover design with small cohorts, where participants took either AL001 then lithium carbonate or the reverse. Each treatment lasted 14 days with three-times-daily dosing and a 14-day washout between periods. These early results support further study of AL001 as a potentially improved lithium formulation for targeting brain exposure.Read AnnouncementClinical Trial - March 16,2026Clinical Trial Phase 2Drug: AL001Announced Date: March 16, 2026Indication: A Next-Generation Lithium Therapeutic Drug Candidate, in Bipolar Disorder PatientsOther Companies Involved: NASDAQ:ALEC AnnouncementAlzamend Neuro, Inc announced the initiation of its Phase II clinical trial evaluating AL001 in patients diagnosed with BD type 1.AI SummaryAlzamend Neuro, Inc. announced it has launched a Phase II clinical trial of AL001 in patients diagnosed with bipolar disorder type 1 (BD‑I). The study will examine whether AL001 is safe and effective at reducing manic and mood symptoms in a larger group of patients than earlier trials. Phase II typically focuses on finding the right dose and gathering early evidence of benefit, and the company plans to use the results to guide future development and potential later‑stage trials. AL001 uses a targeted delivery approach to concentrate lithium in specific brain regions while lowering lithium levels in the rest of the body. The goal is to keep the mood‑stabilizing effects of lithium but reduce risks like kidney and thyroid side effects. Alzamend is also exploring this delivery method for major depressive disorder, Alzheimer’s disease, and PTSD. If AL001 shows positive results, it could offer a more tolerable long‑term treatment option for people with BD‑I and other disorders.Read AnnouncementTop-line data - November 19,2025Top-Line Data Drug: AL001Announced Date: November 19, 2025Target Action Date: Q1 2026Estimated Target Date Range: January 1, 2026 - March 31, 2026Indication: A Next-Generation Lithium Therapeutic Drug Candidate, in Bipolar Disorder PatientsOther Companies Involved: NASDAQ:ALEC AnnouncementAlzamend Neuro, Inc announced that the Topline data expected in first quarter of 2026AI SummaryAlzamend Neuro announced completion of the clinical portion of its first Phase II study of AL001 in healthy subjects and said topline data will be reported in the first quarter of 2026. The company expects these results to be a key readout for AL001’s development. The study compared AL001 head-to-head with a marketed lithium carbonate product to measure lithium levels in blood and specific brain structures. Conducted at Massachusetts General Hospital, the trial used a unique Tesla-engineered head coil for high-resolution, whole-brain lithium imaging to precisely map lithium distribution. Alzamend aims to show that AL001 delivers more lithium to the brain while keeping blood levels lower. If confirmed, this could reduce systemic side effects and possibly remove the need for frequent therapeutic drug monitoring, improving safety for at-risk patients. The company plans Phase II trials in Alzheimer’s, bipolar disorder, major depressive disorder, and PTSD next year, pending these topline results.Read Announcementclinical portion - November 19,2025Clinical Portion Phase 2Drug: AL001Announced Date: November 19, 2025Indication: A Next-Generation Lithium Therapeutic Drug Candidate, in Bipolar Disorder PatientsOther Companies Involved: NASDAQ:ALEC AnnouncementAlzamend Neuro, Inc announced completion of the clinical portion of its first Phase II clinical study of AL001, in healthy human subjects.AI SummaryAlzamend Neuro announced it has completed the clinical portion of its first Phase II study of AL001 in healthy human subjects. The study, run with Massachusetts General Hospital, directly compared AL001 to a marketed lithium carbonate to measure lithium levels in blood and in specific brain structures. Investigators used a specially engineered head coil from Tesla Dynamic Coils BV to create high-resolution, whole-brain lithium images. Those images will help quantify lithium distribution and set disease-specific target doses. Alzamend says the imaging and pharmacokinetic data will guide planned Phase II trials in Alzheimer’s, bipolar disorder, major depressive disorder, and PTSD expected to begin next year. Prior animal work showed higher brain uptake and lower blood lithium with AL001, which could reduce systemic side effects and lessen the need for therapeutic drug monitoring. Topline data are expected in the first quarter of 2026.Read AnnouncementDosing Update - May 29,2025Dosing Update Phase 2Drug: AL001Announced Date: May 29, 2025Indication: A Next-Generation Lithium Therapeutic Drug Candidate, in Bipolar Disorder PatientsOther Companies Involved: NASDAQ:ALEC AnnouncementAlzamend Neuro, Inc. announced the dosing of the first patient of its first Phase II clinical study of AL001, in healthy human subjects. This study follows the successful development of a novel head coil by Tesla Dynamic Coils BV, a key component of the clinical trial.AI SummaryAlzamend Neuro, Inc. has reached a significant milestone by dosing the first patient in its inaugural Phase II clinical trial of AL001, a novel lithium-delivery treatment being studied in healthy human subjects. This clinical trial marks a critical step in evaluating AL001’s potential to improve the delivery of lithium to the brain while reducing overall systemic exposure and side effects. A key element in executing the trial was the successful development of a novel head coil by Tesla Dynamic Coils BV, which is crucial for capturing detailed brain imaging data. This innovative approach, tested in partnership with Massachusetts General Hospital, aims to provide a safer, more efficient way to administer lithium compared to traditional formulations. The study will help determine the optimal path forward for treating conditions such as Alzheimer’s disease, bipolar disorder, major depressive disorder, and PTSD.Read AnnouncementEnrollment Update - May 19,2025Enrollment Update Phase 2Drug: AL001Announced Date: May 19, 2025Indication: A Next-Generation Lithium Therapeutic Drug Candidate, in Bipolar Disorder PatientsOther Companies Involved: NASDAQ:ALEC AnnouncementAlzamend Neuro, Inc. announced the enrollment of the first patient of its first Phase II clinical study of AL001, in healthy human subjects. This study follows the successful development of a novel head coil by Tesla Dynamic Coils BV, a key component of the clinical trial.AI SummaryAlzamend Neuro, Inc. has enrolled the first patient in its Phase II clinical study of AL001 in healthy human subjects. This important step comes after the successful development of a novel head coil by Tesla Dynamic Coils BV, a key tool used in the trial. The study is designed to test AL001’s ability to deliver lithium directly to the brain, potentially offering a more focused treatment with fewer side effects. Researchers hope that by improving how lithium is delivered, AL001 might eliminate the need for frequent blood level monitoring, which can be a significant challenge in current lithium therapies. This trial serves as a baseline to determine whether the new formulation could be effective for conditions such as Alzheimer’s disease, bipolar disorder, major depressive disorder, and post-traumatic stress disorder.Read AnnouncementEXCLUSIVE - May 13,2025Exclusive Phase 2Drug: AL001Announced Date: May 13, 2025Indication: A Next-Generation Lithium Therapeutic Drug Candidate, in Bipolar Disorder PatientsOther Companies Involved: NASDAQ:ALEC AnnouncementAlzamend Neuro Tells Benzinga Co. Initiates First Phase II Clinical Trial Of AL001 Lithium Brain Study Taking Place At Massachusetts General HospitalAI SummaryAlzamend Neuro announced the start of its first Phase II clinical study of AL001 at Massachusetts General Hospital. The trial will involve healthy human subjects to establish a baseline for AL001’s performance. The study is designed to evaluate how well AL001 can deliver lithium directly into the brain compared to existing lithium salts. Researchers hope that this targeted delivery will improve treatment outcomes for disorders such as Alzheimer’s, bipolar disorder, major depressive disorder, and post-traumatic stress disorder, while reducing systemic side effects that are common with traditional lithium therapies. The study also incorporates advanced imaging technology using a novel head coil developed by Tesla Dynamic Coils BV. Topline data from the trial is expected by the end of 2025, which will help determine the next steps in exploring AL001’s potential for safer and more effective brain treatments.Read AnnouncementEXCLUSIVE - May 7,2025Exclusive Drug: AL001Announced Date: May 7, 2025Indication: A Next-Generation Lithium Therapeutic Drug Candidate, in Bipolar Disorder PatientsOther Companies Involved: NASDAQ:ALEC AnnouncementAlzamend Neuro Tells Benzinga Co. Partners With QMENTA To Advance AI-Powered Imaging For Its Phase II Clinical Trial Of AL001 StudyAI SummaryAlzamend Neuro recently announced its collaboration with QMENTA, a company specializing in artificial intelligence-powered medical imaging, to support its Phase II clinical trial of AL001. In this study, QMENTA’s cloud-based platform will manage and analyze imaging data gathered at Massachusetts General Hospital. This partnership is designed to ensure that all data meets regulatory compliance, enhances operational efficiency, and supports robust data management throughout the trial. The study aims to explore whether AL001 can deliver lithium more effectively to the brain, potentially reducing side effects compared to traditional lithium salts. Overall, the collaboration with QMENTA is expected to provide a valuable technological boost, helping researchers gain deeper insights into AL001’s performance and paving the way for more efficient treatments for conditions like Alzheimer’s, bipolar disorder, depression, and PTSD.Read AnnouncementStudy Initiation - March 25,2025Study Initiation Phase 2Drug: AL001Announced Date: March 25, 2025Target Action Date: Q4 2025Estimated Target Date Range: October 1, 2025 - December 31, 2025Indication: A Next-Generation Lithium Therapeutic Drug Candidate, in Bipolar Disorder PatientsOther Companies Involved: NASDAQ:ALEC AnnouncementAlzamend Neuro, Inc. announced its plans to initiate a highly anticipated phase II clinical study of AL001 for treatment of patients with Alzheimer's in the fourth quarter of 2025.AI SummaryAlzamend Neuro, Inc. has announced its plans to start a Phase II clinical study of its drug candidate AL001 for Alzheimer’s patients in the fourth quarter of 2025. This highly anticipated study will examine AL001’s potential to improve the delivery of lithium to the brain while reducing its presence in the bloodstream, a quality that may lessen side effects compared to current lithium salts. The trial, conducted in collaboration with Massachusetts General Hospital, aims to determine whether AL001 can offer targeted brain benefits without the need for frequent lithium monitoring typically required by traditional therapies. If successful, this research could lead to a new treatment option for Alzheimer’s that not only enhances patient safety but also simplifies the management of the disease, potentially improving the quality of life for millions of patients. Read AnnouncementStudy Initiation - March 18,2025Study Initiation Phase 2Drug: AL001Announced Date: March 18, 2025Target Action Date: Q4 2025Estimated Target Date Range: October 1, 2025 - December 31, 2025Indication: A Next-Generation Lithium Therapeutic Drug Candidate, in Bipolar Disorder PatientsOther Companies Involved: NASDAQ:ALEC AnnouncementAlzamend Neuro, Inc. announced its plans to initiate a highly anticipated phase II clinical study of AL001 for treatment of patients with MDD in the fourth quarter of 2025.AI SummaryAlzamend Neuro, Inc. has announced plans to begin a highly anticipated phase II clinical study of AL001 for major depressive disorder (MDD) in the fourth quarter of 2025. This study will explore AL001’s ability to deliver lithium directly to the brain in a more targeted way than current lithium carbonate products. The new approach aims to improve patient outcomes by reducing the need for constant monitoring of lithium levels. In collaboration with Massachusetts General Hospital as its research partner, the study will compare how AL001 affects both lithium blood levels and brain concentrations relative to traditional treatments. Preclinical studies in animals have suggested that AL001 may enhance brain absorption while maintaining lower blood lithium levels, potentially reducing side effects. If successful, this next-generation lithium treatment could provide a safer, more effective option for the millions of Americans suffering from MDD.Read AnnouncementClinical Study - March 11,2025Clinical Study Phase 2Drug: AL001Announced Date: March 11, 2025Target Action Date: Q4 2025Estimated Target Date Range: October 1, 2025 - December 31, 2025Indication: A Next-Generation Lithium Therapeutic Drug Candidate, in Bipolar Disorder PatientsOther Companies Involved: NASDAQ:ALEC AnnouncementAlzamend Neuro, Inc. announced its plans to initiate a phase 2 clinical study of AL001 for patients with post-traumatic stress disorder (PTSD) in the fourth quarter of 2025.AI SummaryAlzamend Neuro, Inc. has announced plans to start a phase 2 clinical study of AL001 for patients with post-traumatic stress disorder (PTSD) in the fourth quarter of 2025. The study aims to explore how AL001 works on the brain and its ability to deliver lithium more effectively compared to standard lithium salts. In collaboration with Massachusetts General Hospital serving as its contract research organization, the research will focus on AL001’s targeted action and potential to reduce systemic side effects in PTSD patients. Prior animal studies have shown promising results, indicating that AL001 can improve brain absorption of lithium while keeping blood lithium levels lower, which may result in a safer and more efficient treatment. This upcoming trial could help show whether AL001 can become a practical treatment option for patients who suffer from PTSD. Read AnnouncementStudy Initiation - March 4,2025Study Initiation Phase 2Drug: AL001Announced Date: March 4, 2025Target Action Date: Q3 2025Estimated Target Date Range: July 1, 2025 - September 30, 2025Indication: A Next-Generation Lithium Therapeutic Drug Candidate, in Bipolar Disorder PatientsOther Companies Involved: NASDAQ:ALEC AnnouncementAlzamend Neuro, Inc. announced its plans to initiate a highly anticipated phase II clinical study of AL001 for treatment of patients with BD, which is expected to commence in the third quarter of 2025.AI SummaryAlzamend Neuro, Inc. announced plans to begin a phase II clinical study of its novel therapy, AL001, for treating patients with bipolar disorder. The study is expected to start in the third quarter of 2025. AL001 is designed to target the delivery of lithium directly to the brain, potentially offering better treatment outcomes with fewer side effects compared to conventional lithium salts. The trial will investigate whether AL001 can provide effective brain absorption while reducing the need for frequent therapeutic drug monitoring. In preclinical studies using mice, AL001 showed promising results with improved lithium distribution in the brain and lower levels in the blood. Alzamend will carry out this study in collaboration with Massachusetts General Hospital, hoping that this innovative approach will lead to a safer and simpler treatment option for the millions affected by bipolar disorder.Read AnnouncementClinical Study - February 25,2025Clinical Study Phase 2Drug: AL001Announced Date: February 25, 2025Target Action Date: Q2 2025Estimated Target Date Range: April 1, 2025 - June 30, 2025Indication: A Next-Generation Lithium Therapeutic Drug Candidate, in Bipolar Disorder PatientsOther Companies Involved: NASDAQ:ALEC AnnouncementAlzamend Neuro, Inc announced its plans to initiate the first of five highly anticipated phase II clinical studies of AL001, with the first study, in healthy human subjects, expected to commence in the second quarter of 2025.AI SummaryAlzamend Neuro, Inc. announced plans to launch the first of five phase II clinical studies for its innovative AL001 treatment. The initial study will involve healthy human subjects and is scheduled to begin in the second quarter of 2025. This trial aims to explore AL001’s unique ability to deliver lithium more efficiently to the brain compared to traditional lithium salts while reducing systemic side effects and the need for regular therapeutic drug monitoring. The research will serve as a baseline for future trials in patients suffering from Alzheimer’s disease, bipolar disorder, major depressive disorder, and post-traumatic stress disorder. Alzamend hopes that the study will pave the way for a safer, more targeted lithium therapy that could significantly improve treatment outcomes. Read AnnouncementProvided Update - February 19,2025Provided Update Drug: AL001Announced Date: February 19, 2025Indication: A Next-Generation Lithium Therapeutic Drug Candidate, in Bipolar Disorder PatientsOther Companies Involved: NASDAQ:ALEC AnnouncementAlzamend Neuro, Inc. announced the completion of a groundbreaking head coil by Tesla Dynamic Coils BV ("Tesla").AI SummaryAlzamend Neuro, Inc. announced a major breakthrough with the completion of a one-of-a-kind head coil developed by Tesla Dynamic Coils BV. This innovative head coil is set to play a critical role in their upcoming Phase II clinical trials. It will provide detailed whole-brain imaging to accurately measure how lithium is absorbed in different brain areas. By capturing precise images, researchers can compare lithium levels in the brain and blood, helping to identify the right doses for conditions like Alzheimer’s, bipolar disorder, major depressive disorder, and PTSD. The advanced imaging tool is expected to give scientists better insights into how lithium works in the brain, which could lead to safer and more effective treatments. This development marks an important step forward in enhancing our understanding of lithium delivery and its potential benefits in treating various neurodegenerative and psychiatric disorders.Read Announcement Alzamend Neuro FDA Events - Frequently Asked Questions Has Alzamend Neuro received FDA approval? As of now, Alzamend Neuro (ALZN) has not received any FDA approvals for its therapy in the last two years. What drugs has Alzamend Neuro submitted to the FDA? In the past two years, Alzamend Neuro (ALZN) has reported FDA regulatory activity for AL001. What is the most recent FDA event for Alzamend Neuro? The most recent FDA-related event for Alzamend Neuro occurred on August 20, 2026, involving AL001. The update was categorized as "Abstract," with the company reporting: "Alzamend Neuro, Inc. announced that an abstract reporting resting-state functional magnetic resonance imaging ("fMRI") findings for AL001, Alzamend's novel organic lithium salt, has been accepted for poster presentation at Neuroscience 2026, the annual meeting of the Society for Neuroscience ("SfN"), to be held November 14–18, 2026 in Washington, DC." What conditions do Alzamend Neuro's current drugs treat? Currently, Alzamend Neuro has one therapy (AL001) targeting the following condition: A Next-Generation Lithium Therapeutic Drug Candidate, in Bipolar Disorder Patients. More FDA Event Resources from MarketBeat FDA Calendars Recent FDA Drug Approval Calendar Upcoming FDA Events & PDUFA Dates Calendar Companies With Recent FDA Events Belite Bio FDA EventsErasca FDA EventsGilead Sciences FDA EventsNuCana FDA EventsUnited Therapeutics FDA EventsAdagene FDA EventsAlnylam Pharmaceuticals FDA EventsGE HealthCare Technologies FDA EventsGenprex FDA EventsHUTCHMED FDA EventsOpus Genetics FDA EventsLigand Pharmaceuticals FDA EventsEthos Technologies Inc. Class A Common Stock FDA EventsRegeneron Pharmaceuticals FDA EventsTvardi Therapeutics FDA Events FDA Event Stage Terminology & Abbreviation Guide NDA: New Drug Application ANDA: Abbreviated New Drug Application sNDA: Supplemental New Drug Application BLA: Biologics License Application sBLA: Supplemental Biologics License Application FDA Approved: Approved by the FDA EMA: European Medicines Agency CE Mark: European Union Certification NMPA: China National Medical Products Administration MHLW: Japanese Ministry of Health FDA Meeting: Consultation with FDA Pre-IND: Pre-Investigational New Drug Meeting Breakthrough Therapy: Special FDA designation for promising therapies Fast Track: Accelerated FDA approval pathway Orphan Drug: Designation for rare disease treatments RPD: Rare Pediatric Disease Designation RMAT: Regenerative Medicine Advanced Therapy DSMB Review: Data Safety Monitoring Board Review IDMC Review: Independent Data Monitoring Committee MAA: MHRA Marketing Authorization Application RTF: Refusal to File (Rejected Application) 510(k): FDA Clearance for Medical Devices Rolling Submission: Staggered regulatory review process Related Companies NextCure FDA Events Atossa Genetics FDA Events Edesa Biotech FDA Events Akari Therapeutics FDA Events Jasper Therapeutics FDA Events Acumen Pharmaceuticals FDA Events Silexion Therapeutics FDA Events NLS Pharmaceutics FDA Events Allarity Therapeutics FDA Events Seres Therapeutics FDA Events Stock Lists Biotechnology StocksCompare Biotech StocksCompare Healthcare StocksCompare Pharmaceutical StocksHealthcare Stocks FDA progress for NASDAQ:ALZN last updated on 8/20/2026 by MarketBeat.com Staff. We continuously monitor for new FDA events and market data. From Our PartnersWhy I'm selling my Snapback Indicator for just $7For Black Friday, Base Camp Trading's Thomas Wood is offering lifetime access to his proprietary Snapback Indi...Base Camp Trading | SponsoredYour free book is about to disappearBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredEvery Starlink dish pays this stockThere's a chip inside every Tesla and Starlink dish that Elon doesn't own. He pays royalties to use it. Now...Behind the Markets | SponsoredDrop these 5 stocks before the market opens tomorrow!The Wall Street Journal called it the "$64 trillion question": is a stock market crash on the way? Weiss Ratin...Weiss Ratings | SponsoredWhat the hell is going on?Porter Stansberry says President Trump is quietly replacing the U.S. dollar without a vote in Congress, and th...Porter & Company | Sponsored6 Men Secretly Changed America’s Money. Now It’s Happening AgainIn 1910, six powerful men secretly met to lay the groundwork for the Federal Reserve, reshaping America's fina...Banyan Hill Publishing | SponsoredURGENT: If you own a home, please review the map below.More than 1,300 red dots are scattered across the country, and 2,800 more are already on the way. Jim Rickards...Paradigm Press | SponsoredCFA: Bank of America Said THISOn January 24th, 2022, Bank of America told Bloomberg something that should terrify every American with a savi...Decentralized Masters | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Alzamend Neuro, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Alzamend Neuro With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Abstract - August 20,2026Abstract Drug: AL001Announced Date: August 20, 2026Indication: A Next-Generation Lithium Therapeutic Drug Candidate, in Bipolar Disorder PatientsOther Companies Involved: NASDAQ:ALEC AnnouncementAlzamend Neuro, Inc. announced that an abstract reporting resting-state functional magnetic resonance imaging ("fMRI") findings for AL001, Alzamend's novel organic lithium salt, has been accepted for poster presentation at Neuroscience 2026, the annual meeting of the Society for Neuroscience ("SfN"), to be held November 14–18, 2026 in Washington, DC.AI SummaryAlzamend Neuro announced that an abstract on AL001, its experimental organic lithium formulation, has been accepted for a poster presentation at Neuroscience 2026, the Society for Neuroscience’s annual meeting in Washington, D.C. The poster, scheduled for November 18, will report findings from a completed Phase 1/2A trial using advanced 7-tesla resting-state functional MRI to examine changes in brain network connectivity after treatment. The randomized crossover study involved healthy volunteers who received AL001 and standard lithium carbonate in separate treatment periods. Researchers also collected blood samples and used MRI and spectroscopy to measure lithium levels and other brain effects. The company says the trial found that AL001 matched standard lithium’s blood levels and may offer a dose-sparing benefit, with the goal of delivering lithium to the brain while reducing exposure elsewhere in the body. These results are being presented as evidence about how AL001 affects the brain; they do not establish its safety or effectiveness for patients. AL001 is being developed for bipolar disorder and other conditions.Read Announcement
Abstract - August 18,2026Abstract Drug: AL001Announced Date: August 18, 2026Indication: A Next-Generation Lithium Therapeutic Drug Candidate, in Bipolar Disorder PatientsOther Companies Involved: NASDAQ:ALEC AnnouncementAlzamend Neuro, Inc. announced that an abstract reporting pharmacokinetic imaging data for AL001, Alzamend's novel organic lithium salt, has been accepted for oral presentation at the International Society for Magnetic Resonance in Medicine ("ISMRM") Workshop on Beyond Protons: Challenges and Advances in X-Nuclei MR, to be held from September 28 – October 1, 2026 at the Universitat Oberta de Catalunya (UOC) in Barcelona, Spain.Read Announcement
Findings Update - April 7,2026Findings Update Drug: AL001Announced Date: April 7, 2026Indication: A Next-Generation Lithium Therapeutic Drug Candidate, in Bipolar Disorder PatientsOther Companies Involved: NASDAQ:ALEC AnnouncementAlzamend Neuro, Inc announced encouraging pharmacodynamic findings from a brain magnetic resonance spectroscopy ("MRS") analysis conducted in healthy human subjects (N=6) in a trial conducted at Massachusetts General Hospital.AI SummaryAlzamend Neuro announced encouraging pharmacodynamic findings from a brain magnetic resonance spectroscopy (MRS) analysis in six healthy human subjects in a trial conducted at Massachusetts General Hospital. The small, early study reported measurable brain changes after dosing, suggesting the investigational treatment produces detectable central nervous system effects. Based on these preliminary results, Alzamend generated pharmacodynamic hypotheses to test in future confirmatory studies. Planned patient groups include people with Alzheimer’s disease, bipolar disorder (BD), major depressive disorder (MDD), and post‑traumatic stress disorder (PTSD). The company highlighted AL001 as a differentiated lithium therapy aimed at addressing a large unmet need in these conditions. These findings are exploratory and come from a very small sample (N=6). Alzamend plans larger, confirmatory trials using MRS and other measures to validate the signals and guide further clinical development of AL001.Read Announcement
Top-line data - March 26,2026Top-Line Data Drug: AL001Announced Date: March 26, 2026Indication: A Next-Generation Lithium Therapeutic Drug Candidate, in Bipolar Disorder PatientsOther Companies Involved: NASDAQ:ALEC AnnouncementAlzamend Neuro, Inc. announced positive topline data from its first Phase II "Lithium in Brain" clinical trial in healthy human subjects, demonstrating that AL001 meets bioequivalence standards while also showing numerically superior lithium delivery to the brain compared to standard lithium carbonate across all 26 measured brain regions including whole brain.AI SummaryAlzamend Neuro announced positive topline results from its first Phase II "Lithium in Brain" trial in healthy volunteers. The company reported that AL001 met bioequivalence standards while also delivering numerically higher lithium levels to the brain than standard lithium carbonate. This advantage was seen across all 26 brain regions measured, including the whole brain, suggesting AL001 can match systemic exposure yet provide greater brain delivery. The study used a randomized crossover design with small cohorts, where participants took either AL001 then lithium carbonate or the reverse. Each treatment lasted 14 days with three-times-daily dosing and a 14-day washout between periods. These early results support further study of AL001 as a potentially improved lithium formulation for targeting brain exposure.Read Announcement
Clinical Trial - March 16,2026Clinical Trial Phase 2Drug: AL001Announced Date: March 16, 2026Indication: A Next-Generation Lithium Therapeutic Drug Candidate, in Bipolar Disorder PatientsOther Companies Involved: NASDAQ:ALEC AnnouncementAlzamend Neuro, Inc announced the initiation of its Phase II clinical trial evaluating AL001 in patients diagnosed with BD type 1.AI SummaryAlzamend Neuro, Inc. announced it has launched a Phase II clinical trial of AL001 in patients diagnosed with bipolar disorder type 1 (BD‑I). The study will examine whether AL001 is safe and effective at reducing manic and mood symptoms in a larger group of patients than earlier trials. Phase II typically focuses on finding the right dose and gathering early evidence of benefit, and the company plans to use the results to guide future development and potential later‑stage trials. AL001 uses a targeted delivery approach to concentrate lithium in specific brain regions while lowering lithium levels in the rest of the body. The goal is to keep the mood‑stabilizing effects of lithium but reduce risks like kidney and thyroid side effects. Alzamend is also exploring this delivery method for major depressive disorder, Alzheimer’s disease, and PTSD. If AL001 shows positive results, it could offer a more tolerable long‑term treatment option for people with BD‑I and other disorders.Read Announcement
Top-line data - November 19,2025Top-Line Data Drug: AL001Announced Date: November 19, 2025Target Action Date: Q1 2026Estimated Target Date Range: January 1, 2026 - March 31, 2026Indication: A Next-Generation Lithium Therapeutic Drug Candidate, in Bipolar Disorder PatientsOther Companies Involved: NASDAQ:ALEC AnnouncementAlzamend Neuro, Inc announced that the Topline data expected in first quarter of 2026AI SummaryAlzamend Neuro announced completion of the clinical portion of its first Phase II study of AL001 in healthy subjects and said topline data will be reported in the first quarter of 2026. The company expects these results to be a key readout for AL001’s development. The study compared AL001 head-to-head with a marketed lithium carbonate product to measure lithium levels in blood and specific brain structures. Conducted at Massachusetts General Hospital, the trial used a unique Tesla-engineered head coil for high-resolution, whole-brain lithium imaging to precisely map lithium distribution. Alzamend aims to show that AL001 delivers more lithium to the brain while keeping blood levels lower. If confirmed, this could reduce systemic side effects and possibly remove the need for frequent therapeutic drug monitoring, improving safety for at-risk patients. The company plans Phase II trials in Alzheimer’s, bipolar disorder, major depressive disorder, and PTSD next year, pending these topline results.Read Announcement
clinical portion - November 19,2025Clinical Portion Phase 2Drug: AL001Announced Date: November 19, 2025Indication: A Next-Generation Lithium Therapeutic Drug Candidate, in Bipolar Disorder PatientsOther Companies Involved: NASDAQ:ALEC AnnouncementAlzamend Neuro, Inc announced completion of the clinical portion of its first Phase II clinical study of AL001, in healthy human subjects.AI SummaryAlzamend Neuro announced it has completed the clinical portion of its first Phase II study of AL001 in healthy human subjects. The study, run with Massachusetts General Hospital, directly compared AL001 to a marketed lithium carbonate to measure lithium levels in blood and in specific brain structures. Investigators used a specially engineered head coil from Tesla Dynamic Coils BV to create high-resolution, whole-brain lithium images. Those images will help quantify lithium distribution and set disease-specific target doses. Alzamend says the imaging and pharmacokinetic data will guide planned Phase II trials in Alzheimer’s, bipolar disorder, major depressive disorder, and PTSD expected to begin next year. Prior animal work showed higher brain uptake and lower blood lithium with AL001, which could reduce systemic side effects and lessen the need for therapeutic drug monitoring. Topline data are expected in the first quarter of 2026.Read Announcement
Dosing Update - May 29,2025Dosing Update Phase 2Drug: AL001Announced Date: May 29, 2025Indication: A Next-Generation Lithium Therapeutic Drug Candidate, in Bipolar Disorder PatientsOther Companies Involved: NASDAQ:ALEC AnnouncementAlzamend Neuro, Inc. announced the dosing of the first patient of its first Phase II clinical study of AL001, in healthy human subjects. This study follows the successful development of a novel head coil by Tesla Dynamic Coils BV, a key component of the clinical trial.AI SummaryAlzamend Neuro, Inc. has reached a significant milestone by dosing the first patient in its inaugural Phase II clinical trial of AL001, a novel lithium-delivery treatment being studied in healthy human subjects. This clinical trial marks a critical step in evaluating AL001’s potential to improve the delivery of lithium to the brain while reducing overall systemic exposure and side effects. A key element in executing the trial was the successful development of a novel head coil by Tesla Dynamic Coils BV, which is crucial for capturing detailed brain imaging data. This innovative approach, tested in partnership with Massachusetts General Hospital, aims to provide a safer, more efficient way to administer lithium compared to traditional formulations. The study will help determine the optimal path forward for treating conditions such as Alzheimer’s disease, bipolar disorder, major depressive disorder, and PTSD.Read Announcement
Enrollment Update - May 19,2025Enrollment Update Phase 2Drug: AL001Announced Date: May 19, 2025Indication: A Next-Generation Lithium Therapeutic Drug Candidate, in Bipolar Disorder PatientsOther Companies Involved: NASDAQ:ALEC AnnouncementAlzamend Neuro, Inc. announced the enrollment of the first patient of its first Phase II clinical study of AL001, in healthy human subjects. This study follows the successful development of a novel head coil by Tesla Dynamic Coils BV, a key component of the clinical trial.AI SummaryAlzamend Neuro, Inc. has enrolled the first patient in its Phase II clinical study of AL001 in healthy human subjects. This important step comes after the successful development of a novel head coil by Tesla Dynamic Coils BV, a key tool used in the trial. The study is designed to test AL001’s ability to deliver lithium directly to the brain, potentially offering a more focused treatment with fewer side effects. Researchers hope that by improving how lithium is delivered, AL001 might eliminate the need for frequent blood level monitoring, which can be a significant challenge in current lithium therapies. This trial serves as a baseline to determine whether the new formulation could be effective for conditions such as Alzheimer’s disease, bipolar disorder, major depressive disorder, and post-traumatic stress disorder.Read Announcement
EXCLUSIVE - May 13,2025Exclusive Phase 2Drug: AL001Announced Date: May 13, 2025Indication: A Next-Generation Lithium Therapeutic Drug Candidate, in Bipolar Disorder PatientsOther Companies Involved: NASDAQ:ALEC AnnouncementAlzamend Neuro Tells Benzinga Co. Initiates First Phase II Clinical Trial Of AL001 Lithium Brain Study Taking Place At Massachusetts General HospitalAI SummaryAlzamend Neuro announced the start of its first Phase II clinical study of AL001 at Massachusetts General Hospital. The trial will involve healthy human subjects to establish a baseline for AL001’s performance. The study is designed to evaluate how well AL001 can deliver lithium directly into the brain compared to existing lithium salts. Researchers hope that this targeted delivery will improve treatment outcomes for disorders such as Alzheimer’s, bipolar disorder, major depressive disorder, and post-traumatic stress disorder, while reducing systemic side effects that are common with traditional lithium therapies. The study also incorporates advanced imaging technology using a novel head coil developed by Tesla Dynamic Coils BV. Topline data from the trial is expected by the end of 2025, which will help determine the next steps in exploring AL001’s potential for safer and more effective brain treatments.Read Announcement
EXCLUSIVE - May 7,2025Exclusive Drug: AL001Announced Date: May 7, 2025Indication: A Next-Generation Lithium Therapeutic Drug Candidate, in Bipolar Disorder PatientsOther Companies Involved: NASDAQ:ALEC AnnouncementAlzamend Neuro Tells Benzinga Co. Partners With QMENTA To Advance AI-Powered Imaging For Its Phase II Clinical Trial Of AL001 StudyAI SummaryAlzamend Neuro recently announced its collaboration with QMENTA, a company specializing in artificial intelligence-powered medical imaging, to support its Phase II clinical trial of AL001. In this study, QMENTA’s cloud-based platform will manage and analyze imaging data gathered at Massachusetts General Hospital. This partnership is designed to ensure that all data meets regulatory compliance, enhances operational efficiency, and supports robust data management throughout the trial. The study aims to explore whether AL001 can deliver lithium more effectively to the brain, potentially reducing side effects compared to traditional lithium salts. Overall, the collaboration with QMENTA is expected to provide a valuable technological boost, helping researchers gain deeper insights into AL001’s performance and paving the way for more efficient treatments for conditions like Alzheimer’s, bipolar disorder, depression, and PTSD.Read Announcement
Study Initiation - March 25,2025Study Initiation Phase 2Drug: AL001Announced Date: March 25, 2025Target Action Date: Q4 2025Estimated Target Date Range: October 1, 2025 - December 31, 2025Indication: A Next-Generation Lithium Therapeutic Drug Candidate, in Bipolar Disorder PatientsOther Companies Involved: NASDAQ:ALEC AnnouncementAlzamend Neuro, Inc. announced its plans to initiate a highly anticipated phase II clinical study of AL001 for treatment of patients with Alzheimer's in the fourth quarter of 2025.AI SummaryAlzamend Neuro, Inc. has announced its plans to start a Phase II clinical study of its drug candidate AL001 for Alzheimer’s patients in the fourth quarter of 2025. This highly anticipated study will examine AL001’s potential to improve the delivery of lithium to the brain while reducing its presence in the bloodstream, a quality that may lessen side effects compared to current lithium salts. The trial, conducted in collaboration with Massachusetts General Hospital, aims to determine whether AL001 can offer targeted brain benefits without the need for frequent lithium monitoring typically required by traditional therapies. If successful, this research could lead to a new treatment option for Alzheimer’s that not only enhances patient safety but also simplifies the management of the disease, potentially improving the quality of life for millions of patients. Read Announcement
Study Initiation - March 18,2025Study Initiation Phase 2Drug: AL001Announced Date: March 18, 2025Target Action Date: Q4 2025Estimated Target Date Range: October 1, 2025 - December 31, 2025Indication: A Next-Generation Lithium Therapeutic Drug Candidate, in Bipolar Disorder PatientsOther Companies Involved: NASDAQ:ALEC AnnouncementAlzamend Neuro, Inc. announced its plans to initiate a highly anticipated phase II clinical study of AL001 for treatment of patients with MDD in the fourth quarter of 2025.AI SummaryAlzamend Neuro, Inc. has announced plans to begin a highly anticipated phase II clinical study of AL001 for major depressive disorder (MDD) in the fourth quarter of 2025. This study will explore AL001’s ability to deliver lithium directly to the brain in a more targeted way than current lithium carbonate products. The new approach aims to improve patient outcomes by reducing the need for constant monitoring of lithium levels. In collaboration with Massachusetts General Hospital as its research partner, the study will compare how AL001 affects both lithium blood levels and brain concentrations relative to traditional treatments. Preclinical studies in animals have suggested that AL001 may enhance brain absorption while maintaining lower blood lithium levels, potentially reducing side effects. If successful, this next-generation lithium treatment could provide a safer, more effective option for the millions of Americans suffering from MDD.Read Announcement
Clinical Study - March 11,2025Clinical Study Phase 2Drug: AL001Announced Date: March 11, 2025Target Action Date: Q4 2025Estimated Target Date Range: October 1, 2025 - December 31, 2025Indication: A Next-Generation Lithium Therapeutic Drug Candidate, in Bipolar Disorder PatientsOther Companies Involved: NASDAQ:ALEC AnnouncementAlzamend Neuro, Inc. announced its plans to initiate a phase 2 clinical study of AL001 for patients with post-traumatic stress disorder (PTSD) in the fourth quarter of 2025.AI SummaryAlzamend Neuro, Inc. has announced plans to start a phase 2 clinical study of AL001 for patients with post-traumatic stress disorder (PTSD) in the fourth quarter of 2025. The study aims to explore how AL001 works on the brain and its ability to deliver lithium more effectively compared to standard lithium salts. In collaboration with Massachusetts General Hospital serving as its contract research organization, the research will focus on AL001’s targeted action and potential to reduce systemic side effects in PTSD patients. Prior animal studies have shown promising results, indicating that AL001 can improve brain absorption of lithium while keeping blood lithium levels lower, which may result in a safer and more efficient treatment. This upcoming trial could help show whether AL001 can become a practical treatment option for patients who suffer from PTSD. Read Announcement
Study Initiation - March 4,2025Study Initiation Phase 2Drug: AL001Announced Date: March 4, 2025Target Action Date: Q3 2025Estimated Target Date Range: July 1, 2025 - September 30, 2025Indication: A Next-Generation Lithium Therapeutic Drug Candidate, in Bipolar Disorder PatientsOther Companies Involved: NASDAQ:ALEC AnnouncementAlzamend Neuro, Inc. announced its plans to initiate a highly anticipated phase II clinical study of AL001 for treatment of patients with BD, which is expected to commence in the third quarter of 2025.AI SummaryAlzamend Neuro, Inc. announced plans to begin a phase II clinical study of its novel therapy, AL001, for treating patients with bipolar disorder. The study is expected to start in the third quarter of 2025. AL001 is designed to target the delivery of lithium directly to the brain, potentially offering better treatment outcomes with fewer side effects compared to conventional lithium salts. The trial will investigate whether AL001 can provide effective brain absorption while reducing the need for frequent therapeutic drug monitoring. In preclinical studies using mice, AL001 showed promising results with improved lithium distribution in the brain and lower levels in the blood. Alzamend will carry out this study in collaboration with Massachusetts General Hospital, hoping that this innovative approach will lead to a safer and simpler treatment option for the millions affected by bipolar disorder.Read Announcement
Clinical Study - February 25,2025Clinical Study Phase 2Drug: AL001Announced Date: February 25, 2025Target Action Date: Q2 2025Estimated Target Date Range: April 1, 2025 - June 30, 2025Indication: A Next-Generation Lithium Therapeutic Drug Candidate, in Bipolar Disorder PatientsOther Companies Involved: NASDAQ:ALEC AnnouncementAlzamend Neuro, Inc announced its plans to initiate the first of five highly anticipated phase II clinical studies of AL001, with the first study, in healthy human subjects, expected to commence in the second quarter of 2025.AI SummaryAlzamend Neuro, Inc. announced plans to launch the first of five phase II clinical studies for its innovative AL001 treatment. The initial study will involve healthy human subjects and is scheduled to begin in the second quarter of 2025. This trial aims to explore AL001’s unique ability to deliver lithium more efficiently to the brain compared to traditional lithium salts while reducing systemic side effects and the need for regular therapeutic drug monitoring. The research will serve as a baseline for future trials in patients suffering from Alzheimer’s disease, bipolar disorder, major depressive disorder, and post-traumatic stress disorder. Alzamend hopes that the study will pave the way for a safer, more targeted lithium therapy that could significantly improve treatment outcomes. Read Announcement
Provided Update - February 19,2025Provided Update Drug: AL001Announced Date: February 19, 2025Indication: A Next-Generation Lithium Therapeutic Drug Candidate, in Bipolar Disorder PatientsOther Companies Involved: NASDAQ:ALEC AnnouncementAlzamend Neuro, Inc. announced the completion of a groundbreaking head coil by Tesla Dynamic Coils BV ("Tesla").AI SummaryAlzamend Neuro, Inc. announced a major breakthrough with the completion of a one-of-a-kind head coil developed by Tesla Dynamic Coils BV. This innovative head coil is set to play a critical role in their upcoming Phase II clinical trials. It will provide detailed whole-brain imaging to accurately measure how lithium is absorbed in different brain areas. By capturing precise images, researchers can compare lithium levels in the brain and blood, helping to identify the right doses for conditions like Alzheimer’s, bipolar disorder, major depressive disorder, and PTSD. The advanced imaging tool is expected to give scientists better insights into how lithium works in the brain, which could lead to safer and more effective treatments. This development marks an important step forward in enhancing our understanding of lithium delivery and its potential benefits in treating various neurodegenerative and psychiatric disorders.Read Announcement